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Abstract
The Calsequestrin (Csq) transgenic mouse model of cardiomyopathy exhibits wide variation in phenotypic progression
dependent on genetic background. Seven heart failure modifier (Hrtfm) loci modify disease progression and outcome. Here
we report Tnni3k (cardiac Troponin I-interacting kinase) as the gene underlying Hrtfm2. Strains with the more susceptible
phenotype exhibit high transcript levels while less susceptible strains show dramatically reduced transcript levels. This
decrease is caused by an intronic SNP in low-transcript strains that activates a cryptic splice site leading to a frameshifted
transcript, followed by nonsense-mediated decay of message and an absence of detectable protein. A transgenic animal
overexpressing human TNNI3K alone exhibits no cardiac phenotype. However, TNNI3K/Csq double transgenics display
severely impaired systolic function and reduced survival, indicating that TNNI3K expression modifies disease progression.
TNNI3K expression also accelerates disease progression in a pressure-overload model of heart failure. These combined data
demonstrate that Tnni3k plays a critical role in the modulation of different forms of heart disease, and this protein may
provide a novel target for therapeutic intervention.
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Introduction
Heart failure is the common final outcome for many forms of
acute and chronic heart disease. The prognosis of heart failure is
highly variable between patients, and the differences in phenotypic
expression (symptoms, disease progression and course, and final
outcome) create difficulties in the construction of predictive models
[1]. Previous research has suggested that genetic factors can
considerably modify the progression and outcome of heart failure
[2]. However, these factors are difficult to identify directly in the
human population because of wide genetic variability, uncontrolla-
ble environmental factors, and the intervention of medical therapy.
We have employed a disease-sensitized mouse model to map
genetic factors that modify the progression and outcome of heart
disease. In the Calsequestrin transgenic mouse, cardiac-specific
overexpression of the calcium binding protein Calsequestrin
(CSQ) leads to dilated cardiomyopathy [3]. This murine model
recapitulates many of the hallmarks of human dilated cardiomy-
opathy including cardiac enlargement, depressed contractile
function, abnormal beta-adrenergic receptor signaling and
premature death [4]. Although all mice that overexpress CSQ
develop dilated cardiomyopathy, disease progression and outcome
varies greatly depending on the genetic background (inbred mouse
strain) harboring the Csq transgene (Csq
tg) [5,6]. These differences
are due to modifier genes whose multiple alleles differentially
modulate the phenotype.
We have exploited these strain-specific phenotypic differences to
map seven different loci (Heart failure modifier or Hrtfm)t h a tm o d i f y
the progression of cardiac dysfunction and the outcome of heart
failure [5–7]. Hrtfm2, mapping to mouse chromosome 3, was
identified in a cross between inbred strain DBA/2J (DBA), which
harbors the original Csq
tg, and C57BL/6 (B6). In this cross, the B6
allele at Hrtfm2 imparted a dominant, disease-accelerating effect on
both cardiac dysfunction (as measured by echocardiography) and
reduced survival [5]. Subsequently, Hrtfm2 was re-identified in a
second cross between DBA/Csq
tg animals and inbred strain AKR/J
(AKR) [7]. In this cross, the AKR allele of Hrtfm2 also imparted a
dominant, disease-accelerating effect on cardiac dysfunction and
survival. The phenotypiceffects of Hrtfm2 were robust, accounting for
30% of the genetic variability for survival and 22% for cardiac
dysfunction. Capitalizing on the ancestral nature of the Hrtfm2 allele
(ie, mapping within a murine haplotype block that has been retained
throughout evolution and now found in multiple inbred strains), we
employed haplotype-sharing analysis to effectively narrow the
candidate interval from 16.5 Mb to 2 Mb, a region containing only
7 known genes [7]. We had previously suggested the Tnni3k gene as
an attractive candidate based on its location within the shared
haplotype interval and its biological significance as a cardiac-specific
kinase that reportedly interacts with cardiac Troponin I (cTnI) [8].
Here we report the molecular characterization of allelic variation at
the murine Tnni3k gene, and present in vivo functional evidence
showing that Tnni3k underlies the heart failure modifier locus, Hrtfm2.
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As part of an effort to identify candidate genes for the Hrtfm loci,
we performed microarray expression analysis of normal heart tissue
from theinbred strainsused inourmapping crosses toidentify genes
showing innate differences in transcript levels. Of the genes
mapping within the Hrtfm2 linkage peak, only one gene exhibited
significantly different transcript levels between the less susceptible
strain DBA and the more susceptible strains B6 and AKR.
Transcript levels of Tnni3k were elevated 12-fold in B6 and AKR
compared with DBA, whereas levels of other transcripts mapping
withinthe intervalwerenotsignificantlydifferent(Figure1A).These
expression differences were validated by more-sensitive qRT-PCR
analysis, where Tnni3k message levels were found to be 25-fold
higher in B6 and AKR strains than those in DBA (Figure 1B). In
parallel, we genetically isolated the Hrtfm2 locus by creating a
congenic line that carried AKR alleles across Hrtfm2 (an
approximately 20 Mb region between rs13477425 and
rs13477504) and DBA alleles throughout the rest of the genome.
Quantitative RT-PCRshowed that Tnni3ktranscript levelsin hearts
from DBA.AKR-Hrtfm2 congenic mice were comparable to levels
observed in B6 and AKR (AKR being the source of the Hrtfm2
locus), and not that seen in DBA (the genomic background),
suggesting that the Tnni3k expression differences were driven by cis-
acting sequence elements within the Hrtfm2 locus, rather than trans-
acting factors mapping elsewhere in the genome.
We analyzed heart tissue prepared from six inbred mouse
strains to determine if these differences in levels of Tnni3k
transcript would be observed at the protein level. We chose three
additional strains that shared either the DBA or B6 haplotype at
Tnni3k (Table S1). As predicted by the transcript levels, robust
levels of TNNI3K protein were detected in B6, AKR, 12961/SvJ
(129) and the DBA.AKR-Hrtfm2 congenic, which share the B6
haplotype. Surprisingly, no apparent protein was detected for
DBA, C3H/HeJ and BALB/cByJ (BALB/c) strains, which share
the DBA haplotype (Figure 1C). Therefore, within the limits of
detection of the antiserum, TNNI3K protein was apparently
absent from hearts of strains sharing the DBA haplotype at the
Tnni3k locus. The latter strains effectively represent Tnni3k null or
extreme hypomorphic genotypes with no apparent effect on
development or survival, and with no obvious pathological
consequence.
The Tnni3k coding region of the mapping strains differed by a
single, relatively conservative, non-synonymous coding SNP
(rs30712233, T659I). By sequencing Tnni3k cDNA from the
strains, we noted another, more consequential, strain-specific
sequence difference. All strains sharing the B6 haplotype showed a
single major transcript identical to the published cDNA. By
contrast, all strains sharing the DBA haplotype exhibited a mixture
of two transcripts consisting of the published transcript and a
second transcript containing a 4-nucleotide insertion between
exons 19 and 20 (Figure 2A). This insertion was not present in the
genomic DNA, but instead represented the addition of the first 4
nucleotides from intron 19 into the Tnni3k transcript. The
insertion created a frameshift resulting in a premature termination
codon immediately downstream (Figure 2B). We determined that
the frameshifted transcript accounted for approximately 70% of
the message in DBA heart mRNA, but was not present in B6 or
AKR (Figure 2C). This transcript was not found in any of the EST
databases for mouse or any other species, suggesting that it
represented an aberrant message created by defective splicing,
possibly caused by the use of a second ‘gt’ splice donor site 4
nucleotides downstream of the normal donor site.
The genomic region surrounding exons 19 and 20 harbors over
50 SNPs. Although in principle any of these could have caused the
aberrant splicing, we focused on the SNP nearest to the splice
donor junction. B6 and related strains (AKR, 129, MRL) possess
an ‘a’ nucleotide at rs49812611, whereas DBA and related strains
(A/J, C3H/HeJ (C3H), BALB/c) possess a ‘g’. This SNP lies at the
+9 position for the normal splice site, but importantly, this SNP
lies at the +5 position with reference to the aberrant splice site.
Thus, DBA and related strains harbor the consensus ‘g’ nucleotide
at the +5 position for the aberrant site. During mRNA processing,
the ‘g’ at the +5 splice donor position pairs with a ‘c’ in the U1 or
U6 snRNA, resulting in a preference for ‘g’ at this position. Weight
matrix scores for splice donor strength [9,10] for each possible
splice donor site confirmed that the second (aberrant) splice site
was the strongest splice site in the region only when the ‘g’
nucleotide is present at rs49812611 (Figure 2D).
We tested the hypothesis that rs49812611 is the cause of
aberrant splicing using an in vitro splicing system. Genomic DNA
spanning exons 18 through 20 from both B6 and DBA were sub-
cloned and transfected into 293T cells (Figure 3A). These in vitro
constructs recapitulated the splicing pattern observed in vivo,
confirming that the splicing defect was caused by cis-acting
sequences residing within the cloned 4 kb genomic fragment
(Figure 3B). Site-directed mutagenesis was used to investigate the
role of rs49812611 in aberrant splicing. A single change at this
SNP completely reversed the splicing pattern. DBA genomic DNA
altered to carry the ‘a’ allele at rs49812611 generated no aberrant
splice product, whereas the B6 DNA carrying the ‘g’ allele
exhibited the aberrant product (Figure 3B). These results showed
that rs49812611 was responsible for the presence or absence of the
aberrantly spliced message, although the extent of aberrant
splicing may be modulated by other flanking sequence variation.
Since Tnni3k was originallyidentified asa positional candidate for
Hrtfm2 due to differences in transcript levels between the mapping
strains, we hypothesized that nonsense-mediated decay (NMD) was
responsible for the drastically reduced levels of the frameshifted
message seen in DBA. We investigated this in the mouse
cardiomyocyte cell line, HL-1 [11], which shares the DBA
haplotype at Tnni3k. We first confirmed that HL-1 cells expressed
both aberrant and normal Tnni3k at levels comparable to wild-type
DBA hearts, with the majority of the message being the aberrant
variant that includes the 4-nucleotide insertion. HL-1 cardiomyo-
cyte cells were then treated with either cycloheximide and emetine,
two drugs commonly used to block NMD [12]. Treatment with
either drug increased the level of aberrantly spliced transcript
relative to the normally spliced message (Figure 4A). As predicted,
these treatments increased levels of total Tnni3k mRNA 16-fold
Author Summary
Heart failure is the common final outcome of many forms
of acute and chronic heart disease. The prognosis of heart
disease is highly variable between patients, and these
differences in the phenotypic expression (symptoms,
course, and final outcome) are in part due to genetic
factors that have proven difficult to directly identify in the
human population. To overcome this limitation, we
employed a disease-sensitized mouse model of dilated
cardiomyopathy to identify genes that modify the
progression and outcome of the phenotype. Here we
report the identification of a novel heart disease modifier
gene, Tnni3k, that accelerates disease progression in two
distinct mouse models of cardiomyopathy. This gene
appears to play a critical role in modulating heart disease
phenotypes and may provide a novel target for therapeu-
tic intervention.
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differences in transcript levels between strains.
Although these experiments determined the molecular mecha-
nism underlying the observed differences in Tnni3k transcript
levels, they did not address the in vivo role of Tnni3k in the
progression of cardiomyopathy. We next investigated whether
Tnni3k was the gene underlying the Hrtfm2 locus. We created
transgenic mouse lines that expressed human TNNI3K protein in
the heart. TNNI3K protein is highly conserved between human
and mouse (91% identity), and transgenic expression of the human
transcript enabled discrimination between the endogenous murine
transcript and that derived from the transgene. Three independent
founder lines were created, and qRT-PCR indicated that the
human transgene was expressed at levels ranging from 5 to 20-fold
above the endogenous B6 mouse transcript, depending on the
founder. F1 generation mice from all three lines survived over a
year, and cardiac function in 12 and 21-week transgenic animals
were indistinguishable from wild-type animals. Consequently,
TNNI3K expression alone did not result in overt cardiomyopathy
or decreased survival due to heart failure. This was not
unexpected, since in the absence of the Csq transgenic disease-
sensitizer, there were no measurable differences in heart function
between B6 and DBA animals, even though B6 express robust
levels of TNNI3K whereas DBA shows no detectable protein.
By repeated backcrosses to DBA, the TNNI3K transgenes were
introgressed into the DBA background that shows no detectable
endogenous murine TNNI3K protein to test the hypothesis that in
the presence of the Csq transgenic sensitizer, increased expression of
TNNI3K would accelerate disease progression. The backcrossed
transgenic lines continued to express robust levels of the human
TNNI3K protein (Figure S1). Two lines were chosen for all
subsequent experimental crosses, and phenotypic data from N5 (or
N6) animals from both lines were combined, as there was no
discernable difference inthe data derived from eithertransgenic line.
In addition to an apparently normal lifespan, TNNI3K transgenic
animals did not show any signs of cardiac pathology by
echocardiography. By contrast, expression of TNNI3K in the
context of the Csq transgenic sensitizer resulted in profoundly
premature death (Figure 5). Of the four possible genotypes from a
cross between Csq (sensitizer) and TNNI3K (modifier) transgenic
lines, only the double transgenic mice showed a decrease in survival
(p,0.00001). The observed survival differences were profound. All
other genotypes survived on average at least 150 days, but all
animals expressing both Csq and TNNI3K died within 21 days. This
extreme premature death phenotype resembled that which we had
previously observed whenattemptingtointrogresstheCsqtransgene
into the B6 background, which exhibits robust levels of endogenous
mouse TNNI3K protein [5]. Starting with the sensitizer in the DBA
background [4], we were unable to move the Csq transgene beyond
the second generation, as N2 animals died within 40 days,
precluding further backcrosses with B6 mice [5].
We next determined whether natural levels of the murine
TNNI3K protein would also exhibit disease-accelerating effects.
This was investigated by crossing the congenic mice harboring the
AKR allele at Hrtfm2 with mice containing the Csq transgene, both
held for many generations in the DBA background. The progeny
from this cross would harbor a only single AKR allele of Tnni3k,
the appropriate genotype for Hrtfm2 which exhibited dominant
effects in the original mapping crosses [5,7]. When the congenic
mice DBA.AKR-Hrtfm2, were crossed with the Csq sensitized mice,
the Csq
tg offspring with even only a single AKR Hrtfm2 allele
showed a decrease in survival (on average 107 days) compared to
Figure 1. Tnni3k mRNA and protein expression varies significantly between mouse strains. (A) Affymetrix microarray analysis identified
only one gene on murine chromosome 3 with a significant expression change between B6, AKR, and DBA. Two genes flanking Tnni3k (Cryz and
Lrrc44) that are expressed at similar levels in all strains are shown, as well as two control genes, Actb (b-actin) and Gapdh. (B) qRT-PCR confirms
expression differences identified by microarray analysis. TaqMan qRT-PCR of Tnni3k from 5 wild-type mouse hearts from each strain confirms that
transcript levels are higher (approximately 25-fold) in B6 and AKR compared to DBA (**p.0.0001 and *p.0.001). Three hearts from the Hrtfm2
congenic line harboring AKR alleles at the Tnni3k locus on a DBA genetic background (DBA.AKR-Hrtfm2) shows transcript levels similar to B6 and AKR
hearts, which is significantly higher than observed in DBA hearts (**p.0.0001). Actb served as an endogenous control. Error bars indicate standard
error of the mean (SEM). (C) Western blot analysis shows that three strains that share the DBA haplotype at Tnni3k show no detectable TNNI3K
protein, while three strains with the B6 haplotype show robust expression. The DBA.AKR-Hrtfm2 congenic mouse shows high expression as predicted
based on RNA expression. Receptor tyrosine kinase TEK was used as a protein loading control.
doi:10.1371/journal.pgen.1000647.g001
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The Csq-sensitized Hrtfm2 congenic line also survived longer than
Csq-sensitized F1(DBA/B6) animals, which survived on average to
only 50 days [5]. In the original mapping cross, Hrtfm2 contributed
approximately 30% of the genetic variance towards the survival
trait [5]. Thus, as expected, the isolated B6/AKR Hrtfm2 allele
contributed a robust but only partial effect on reduced survival
when compared to the F1 animals, as other modifier loci had been
crossed out of the congenic line.
To determine whether the premature death was related to
cardiac dysfunction, we performed echocardiography on animals
with all four possible genotypes resulting from cross between the
Csq and TNNI3K transgenic lines. Echocardiography was per-
formed at 14 days, the earliest possible age for reproducible
echocardiographic data. Due to the extremely accelerated disease
course and profound reduction in survival, only six of fourteen
double transgenic mice survived to their scheduled 14-day
echocardiogram. Fractional shortening in these TNNI3K
tg/Csq
tg
mice was significantly decreased compared to the other three
genotypes of animals (P,0.0232), demonstrating severely abnor-
mal heart function of the double transgenic animal (Figure 6A and
6B, Table S2). Even by 14 days, hearts from the TNNI3K
tg/Csq
tg
mice were larger than those of the other genotypes, and by
histological staining showed obvious chamber dilation (Figure 6C).
Thus, the double transgenic animals developed dilated cardiomy-
opathy by 14 days (or earlier) and all mice of this genotype died
before this or shortly thereafter due to heart failure. Many of the
double transgenic animals displayed bradycardia (a severe slowing
of the heart rate), clearly evident in the echocardiograms. This
phenotype, while a feature of the natural disease progression in the
Csq transgenic model, is normally observed only in adult animals
just prior to heart failure [5]. Thus, this hallmark of the natural
progression of the Csq transgenic model is also greatly accelerated
with overexpression of TNNI3K.
We also investigated the echocardiographic parameters of the
DBA.AKR-Hrtfm2/Csq
tg (see Figure 5). Echocardiography per-
formed on these mice at 4 and 8 weeks of age showed decreased
fractional shortening in DBA.AKR-Hrtfm2/Csq
tg mice compared
to the DBA/Csq
tg littermates, indicating more severe level of
cardiomyopathy (Figure 7, Table S3). Furthermore, from age 4 to
8 weeks, percent fractional shortening decreased more rapidly in
DBA.AKR-Hrtfm2/Csq
tg mice (36%, p=0.0004) than the litter-
mates (18%, p=0.186), suggesting that the presence of even a
single AKR-Hrtfm2 locus (essentially half the normal AKR/B6
level of TNNI3K expression) can accelerate the progression of the
Csq-induced cardiomyopathy.
We next investigated whether TNNI3K expression would
exhibit a disease accelerating effect in a model of cardiomyopathy
that was unrelated to Calsequestrin over-expression. Transverse
aortic constriction (TAC) induces left ventricular hypertrophy in
response to pressure overload [13]. We performed TAC on
TNNI3K transgenic animals and wild-type littermate controls.
Figure 2. Aberrant splicing of Tnni3k in hearts from DBA mice. (A) Sequencing chromatogram shows the exon 19–20 boundary in Tnni3k
cDNA from B6 and DBA hearts. The dashed line shows the first base of the 4 nucleotide cDNA insertion (GTTT) derived from intron 19. The small
proportion of properly spliced transcript in DBA can be seen as overlapping sequence after the dashed line. (B) Sequence of exon 19 and 20 with
flanking intronic sequence with amino acid translation for both B6 (1
st site/normal) and DBA (2
nd site/aberrant). The 4 nucleotide GTTT insertion is
shown in bold, and rs49812611 is underlined. (C) Fluorescent fragment analysis was used to determine the fraction of aberrant splicing in DBA.
Almost 70% of total message in DBA was aberrantly spliced, while no aberrant splicing was observed in B6 and AKR. (D) Weight matrix scores [9,10]
for the different splice donor sites are shown.
doi:10.1371/journal.pgen.1000647.g002
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weeks following TAC surgery. At 4 and 8 weeks post-surgery, the
transgene-positive mice showed greater diastolic and systolic
dysfunction (increased left-ventricular end diastolic diameter
(LVEDD) and left-ventricular end systolic diameter (LVESD)),
and significantly reduced fractional shortening compare to the
control mice (Figure 8A–8C, Table S4). This confirmed that
TNNI3K expression has a detrimental effect on heart function
outside the context of the transgenic Csq sensitizer.
Discussion
We had previously mapped 7 loci (Hrtfm1-7) that modify heart
disease progression using the Calsequestrin (Csq) transgenic mouse
model [5–7]. Here we report Tnni3k (cardiac Troponin I-interacting
kinase) as the gene underlying Hrtfm2. We have shown that the
murine Tnni3k locus harbors an ancestral SNP in intron 19 that
activates a cryptic splice site, generating an aberrant transcript that
undergoes NMD, leading to drastically reduced message levels and
Figure 3. The sequence at rs49812611 is responsible for aberrant Tnni3k splicing. An in vitro system was used to test the role of the intron
19 SNP (rs49812611) in aberrant splicing between exons 19 and 20 in DBA compared to B6. (A) Schematic representation of the Tnni3k exon 18–20 in
vitro splicing construct used to test aberrant splicing. Genomic fragments (4 kb) from DBA and B6 including exons 18, 19, and 20 were amplified and
cloned into a splicing vector. Additionally, site-directed mutagenesis was used to alter the sequence at the SNP in both constructs. Splicing constructs
were transfected into 293T cells and RNA was harvested after 48 hours. (B) Analysis of Tnni3k splicing reveals aberrant splicing of the in vitro DBA
construct closely resembles splicing in wild-type DBA hearts but the aberrant transcript is absent with the B6 in vitro construct. When the critical
nucleotide at the +9 position in intron 19 is exchanged between the constructs, the splicing pattern follows the sequence at the SNP, demonstrating
that the sequence at rs49812611 is responsible for the splicing defect.
doi:10.1371/journal.pgen.1000647.g003
Figure 4. Nonsense-mediated decay is responsible for reduced Tnni3k transcript levels. HL-1 cardiomyocytes were treated with emetine
or cycloheximide to block NMD. RNA was isolated from cells 24 hours after treatment. The ratio of aberrant to wild-type transcripts was calculated
and qRT-PCR was used to determine Tnni3k message levels relative to actb. Cells that were mock-treated with the drug-diluent buffer solution acted
as a control. (A) Either emetine or cycloheximide treatment preferentially increases levels of the aberrantly spliced message relative to the normally
spliced message (*p,0.01). (B) Either emetine or cycloheximide treatment increased the total levels of Tnni3k message approximately 16-fold above
mock-treated cells (**p,0.001).
doi:10.1371/journal.pgen.1000647.g004
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inbred mouse strains sharing the same haplotype at Tnni3k,
drastically reduced levels of TNNI3K protein have no obvious
effect on normal development or physiology, suggesting that any
trace amounts of protein that remain are sufficient for its normal
function, or that the lack of protein is compensated by functional
redundancy of another gene. In vivo transgenic and congenic
mouse lines confirm that TNNI3K levels are a significant
determinant of the rate of disease progression and outcome, since
expression of this protein accelerates disease progression in two
independent and unrelated models of cardiomyopathy. However,
we did not observe a simple, linear relationship between the level
of TNNI3K transgenic overexpression and the strength of the
modifying effect. In these models, the levels of overexpression in
the transgenic lines may have crossed the threshold required for
maximal phenotypic effects.
The modifying effects of TNNI3K expression were not
dependent on the allele at the nonsynonymous coding SNP
(rs30712233, T659I). DBA and most inbred mouse strains
encode Threonine at this position. Most other species also
encode Threonine at the homologous position. By contrast, B6
and AKR inbred strains encode the Isoleucine variant. The
human TNNI3K transgene employed in the validation exper-
iments coincidentally encodes the highly conserved Threonine
variant. The modifying effects of the human transgene
carrying the conserved variant (695T) directly parallel, and
are even stronger, than those observed using the congenic line
containing the B6/AKR variant (695I). Thus, robust pheno-
type modifying effects were observed independent of the
murine Tnni3k coding variant. Nonetheless, these experiments
did not address whether the 695I polymorphism also alters
TNNI3K protein function.
TNNI3K was identified as a cardiac-specific protein kinase that
interacted with cardiac Troponin I (cTnI) in the yeast-two hybrid
interaction assay [8], however, cTnI has not been established as a
phosphorylation target. TNNI3K protein contains seven ankyrin
repeats in the N-terminus followed by a dual-specificity protein
kinase domain and a short C-terminal serine-rich domain. The
overall domain structure of TNNI3K resembles that of Integrin-
linked Kinase (ILK). ILK mediates communication from the
cellular matrix to intracellular signaling molecules such as PKB
and GSK3b, and plays important roles in cardiac growth,
contractility and repair [14,15]. Sequence and structural homol-
ogy might imply similar functions for TNNI3K. A yeast two-
hybrid interaction screen with a C-terminal fragment of TNNI3K
identified several additional sarcomeric proteins as putative
binding partners such as cardiac a-actin and myosin binding
protein C [8]. These studies suggest that TNNI3K might
modulate sarcomere function through interactions with key
components of the sarcomeric complex. However, to date, none
of these proteins has been validated as a phosphorylation target of
TNNI3K in cardiomyocytes, and the in vivo function of TNNI3K
remains unknown.
Recently, expression of TNNI3K was shown to be protective
in a different cardiomyopathic disease context [16,17]. In a
murine model of cardiac ischemia, intramyocardial transplan-
tation of Tnni3k-overexpressing P19CL6 cells promoted
cardiomyogenesis and improved cardiac function. We note
that P19CL6 cells were originally derived from the C3H
lineage of mice [18], which share with DBA, the ‘‘null’’
haplotype for Tnni3k (see Figure 1). Thus, the resulting
phenotype may have been due to the restoration of Tnni3k
expression in otherwise null cells, rather than to overt
overexpression of the gene. A locus for susceptibility to
Figure 5. TNNI3K expression leads to premature death in the Csq transgenic model of cardiomyopathy. A Kaplan-Meier survival graph
shows the outcomes of different genotypic groups resulting from a cross between TNNI3K
tg and Csq
tg transgenic animals. Survival is severely
decreased for double positive transgenics (TNNI3K
tg/Csq
tg) to an average of 17 days with a range from 15 to 21 days. Csq
tg mice on congenic
background (DBA. AKR-Hrtfm2 : DBA genome except Hrtfm2 loci) survived to 107 days on average. Nearly all mice with other genotypes, including
both single positives (TNNI3K
tg and Csq
tg) survived to at least 150 days, at which point the animals were sacrificed and the experiment terminated.
Survival of TNNI3K
tg/Csq
tg and Congenic/Csq
tg compared to the three other groups was significantly decreased (p,0.00001). F1(DBA/B6) Csq
tg
animals died much sooner (average only 50 days) when compared to Csq
tg in the background of the isolated (congenic) Hrtmf2 locus. The number of
animals in each group is as follows: Wild type, n=18; TNNI3K
tg, n=18; Csq
tg, n=18; Congenic/Csq
tg, n=11; TNNI3K
tg/Csq
tg, n=12, F1(DBA/B6) Csq
tg,
n=58 (F1 data from [5]).
doi:10.1371/journal.pgen.1000647.g005
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distal mouse chromosome 3 (Vms1, viral myocarditis suscep-
tibility locus) that virtually overlaps Hrtfm2 and which includes
Tnni3k in its confidence interval [17]. In this disease model,
inbred strain C57BL/10 provides the protective allele at the
locus, and strain A/J provides the susceptibility allele.
Assuming that Tnni3k also underlies the Vms1 locus, viral-
induced myocarditis might represent another disease context
where expression of TNNI3K is protective. These combined
data suggest that expression of TNNI3K may be detrimental in
certain pathological conditions such as pressure overload or
aberrant sarcomeric calcium regulation, but protective in other
disease contexts. In either scenario, TNNI3K appears to play a
critical role in modulating disease progression and outcome in
heart disease.
Since protein kinases are critical cell cycle regulators, kinase
inhibitors have become a major avenue for the development of
novel cancer therapeutics. TNNI3K may be an ideal candidate for
the development of small molecule kinase inhibitors for categories
of heart disease where TNNI3K expression is detrimental. In these
cases, selective inhibition of TNNI3K would be particularly useful
as it might slow disease progression, which may prove beneficial in
treating individuals with rapidly progressing disease. In other
scenarios of disease, augmentation of TNNI3K activity or protein
levels may instead prove beneficial. Further investigation of
TNNI3K function in these and other cardiomyopathic mouse
Figure 6. TNNI3K expression leads to severely impaired cardiac function in the Csq
tg transgenic model of cardiomyopathy. M-mode
echocardiograms were performed on 14-day-old mice from a cross between TNNI3K
tg and Csq
tg transgenic animals. (A) Representative
echocardiograms showed that the double positive transgenic mice display severe left ventricle systolic dysfunction and chamber dilation (in the
bottom). (B) Analysis of the echocardiogram data shows that fractional shortening (FS), which indicates cardiac function, is decreased in double
positive transgenic mice compared to other littermates. Data is represented by mean6error of the mean (SEM) for wild type, TNNI3K
tg, Csq
tg, and
TNNI3K
tg/Csq
tg. The number of animals in each group is as follows: wild type, n=12; TNNI3K
tg,n=8 ;Csq
tg, n=14; and TNNI3K
tg/Csq
tg, n=6. (C) Whole
hearts and representative histological sections are shown stained with Masson Trichome. Consistent with echocardiographic data, the TNNI3K
tg/
Csq
tgmouse hearts show severe dilation in comparion to TNNI3K
tg and Csq
tg single transgenic animals.
doi:10.1371/journal.pgen.1000647.g006
Figure 7. One copy of the AKR allele at Hrtfm2 leads to an
acceleration of cardiomyopathy in the Csq
tg transgenic model
of cardiomyopathy. Echocardiographic analysis showed decreased
fractional shortening in Csq
tg transgenic mice on the congenic
background (DBA. AKR-Hrtfm2) at 4 and 8 weeks of age, compared to
their littermates with DBA Hrtfm2 alleles (p=0.263 and 0.016). From 4 to
8 weeks, the fractional shortening was decreased 36% in Csq
tg/
Congenic mice (p=0.0004), and 18% in Csq
tg/DBA mice (p=0.186). The
number of animals in each group was as follows: Csq
tg/DBA, 4 weeks,
n=7; 8 weeks, n=7; Csq
tg/Congenic, 4 weeks, n=9; 8 weeks, n=6. Data
is represented by mean6SEM.
doi:10.1371/journal.pgen.1000647.g007
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normal and pathological contexts, and may provide a novel target
for therapy for heart disease.
Methods
Animal care and handling
All mice were handled according to approved protocol and
animal welfare regulations of the Institutional Review Board
at Duke University Medical Center. All inbred mouse strains
used in the course of this study were obtained from Jackson
Laboratory (Bar Harbor, ME). Transgenic mice overexpress-
ing Csq [3] were maintained on a DBA/2J genetic back-
ground.
DBA.AKR-Hrtfm2 congenic mouse
Through repeated backcrossing to DBA/2J, a congenic
mouse was created which retains AKR genomic DNA at the
Hrtfm2 locus in the DBA genetic background. At generation
N2, breeders were selected which were heterozygous at Hrtfm2
and homozygous DBA at the other mapped modifier loci [7].
Genome-wide SNP genotyping was carried out using the
Mouse MD linkage panel with 1449 SNPs (Illumina, San
Diego, CA). By generation N6, the animals were homozygous
for DBA alleles throughout the genome and only showed
heterozygosity for an approximately 20 Mb interval on
chromosome 3, the region containing Hrtfm2.O n c ew eh a d
reached the generation N10 backcross, the DBA.AKR-Hrtfm2
mouse was maintained by intercross.
Mouse RNA isolation, microarray analysis, and qRT-PCR
Whole hearts removed from age- and sex-matched wild type
animals from each of the three primary strains (B6, DBA, AKR)
were used to examine RNA transcript levels. Total RNA was
isolated using the RNeasy Kit (Qiagen, Valencia, CA). Microarray
analysis was done on an Affymetrix Mouse probe set (Mouse 430
2.0 Array, Affymetrix, Santa Clara, CA). Analysis was done using
GeneSpring GX 7.3 Expression Analysis (Agilent Technologies,
Santa Clara, CA). For the TaqMan expression analysis, total RNA
was extracted from whole mouse hearts using TRIzol reagent
(Invitrogen, Carlsbad, CA). cDNA was synthesized from 1 mg total
RNA using the High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA) and used as the template for qRT-
PCR. Tnni3k cDNA was amplified using the predesigned gene
expression assay (TaqMan, ABI, assay ID: Mm01318633_m1).
Beta-actin (Actb) was used as the endogenous control (TaqMan,
ABI, catalogue number 4352341E). All amplifications were carried
out in triplicate on an ABI Prism 7000 Real Time PCR system
and analyzed with ABI software. All statistical analyses were done
using an unpaired, two-tailed T-test.
Figure 8. TNNI3K expression leads to systolic dysfunction in a surgically induced model of cardiomyopathy. Echocardiography was
performed prior to transverse aortic constriction (TAC) and at 4- and 8-weeks post TAC surgery. (A) Left-ventricular end diastolic diameter (LVEDD), (B)
left-ventricular end systolic diameter (LVESD), and (C) FS were compared between TNNI3K
tg mice (n=11) and wild-type littermates (n=13) at 4 and 8
weeks post-TAC. LVEDDs were significantly higher in TNNI3K
tg mice at 4 and 8 weeks, but were not statistically different prior to surgery. Similarly,
fractional shortening was significantly decreased in TNNI3K
tg mice at both 4 and 8 weeks following surgery. Data is represented by mean6SEM.
doi:10.1371/journal.pgen.1000647.g008
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Whole heart protein lysates were prepared using flash-frozen
heart tissue resuspended in lysis buffer with protease inhibitors.
Lysates were analyzed by SDS-PAGE and Western blot performed
with standard methods. A polyclonal peptide antiserum was
developed to the C-terminal 14 amino acids of mouse TNNI3K
protein (LHSRRNSGSFEDGN). Antiserum from 2 rabbits was
purified on a Protein A column (GenScript, Piscataway, NJ).
TNNI3K antibody was used at a 1:1000 dilution in TBST with
5% dry milk. Secondary anti-rabbit antibody conjugated to HRP
followed by incubation with Pierce SuperSignal West Pico
Chemiluminescant Substrate (Thermo Fisher Scientific, Rockford,
IL) and exposure to X-OMAT film (Kodak) to visualize protein
bands. Western blot analysis was used to confirm specificity of the
antibody. As predicted, the mTNNI3K antibody detects a 90 kDa
protein from lysates prepared from 293T cells transiently
transfected with a full length Tnni3k expression vector and in
protein lysates from wild-type mouse hearts.
Fluorescent RT-PCR assay
cDNAs were subjected to qRT-PCR using primers designed to
detect either a 116 bp or a 120 bp cDNA PCR product. The
forward primer was targeted 25 bp upstream of the predicted 4
base insertion and was fluorescently labeled: 59-6FAM-
AGATTTCTGCAGTCCCTGGAT-39 while the unlabeled re-
verse primer was targeted 48 bp downstream of the predicted 4
base insertion with the sequence: 59-AAGACATCAGCCTT-
GATGGTG-39. Accumulation of both fragments was quantified
using the GeneMapper analysis program on the ABI Prism 3730
DNA Sequencer (Applied Biosystems). Ratios of properly spliced
and mis-spliced products were calculated based on relative
amplification of both cDNA products.
Cloning of mTnni3k splicing constructs, cell culture, and
transfection
To create the Tnni3k genomic splicing constructs, DBA genomic
DNA and B6 BAC clone RP23-180023 were used as templates to
generate genomic 4 kb fragments that included part of intron 17,
exon 18, intron 18, exon 19, intron 19, exon 20 and part of intron
20. The sequence of the forward PCR primer was 59-
ACTTACTTATGTGCTTCTCTTAGTTATGTGC-39; the re-
verse primer was 59-GGATTTAAACATAGGTGTGTACC-
TAATTGT-39. PCR products were sub-cloned into pSPL3
(Invitrogen). Clones were verified by direct sequencing. Human
embryonic kidney HEK293T (293T) cells (ATCC, Manassas, VA)
were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM, Gibco) containing 10% fetal bovine serum at 37uCi n
5% CO2. Cells were grown on 35 mm
2 plates and transfected with
1 mg plasmid DNA using FuGene reagent (Roche, Indianapolis,
IN) according to the manufacturer’s protocol. RNA was extracted
with TRIzol (Invitrogen) 24 hr post-transfection and RT-PCR was
carried out using standard methods.
In vitro splicing assay
HEK293T cells were grown to approximately 80% confluence
in 6-well plates, then transfected using with 1 mg of DBA- or B6-
pSPL3 plasmid mixed with FuGene reagent. All transfections were
performed in triplicate. Total RNA was extracted with TRIzol
20 hr post-transfection. RT-PCR was carried out using standard
methods. Ratios of properly spliced and aberrantly spliced
products for the Tnni3k construct were determined by the
fluorescent RT-PCR assay described above.
Site-directed mutagenesis
A single base was changed at rs49812611 (IVS19+9), in the
DBA-pSPL3 construct (GRA) and the B6-pSPL3 construct
(ARG) using the QuikChange Site-Directed Mutagenesis Kit
(Stratagene, LaJolla, CA) with PfuTurbo proofreading DNA
polymerase. All clones were sequenced to verify proper incorpo-
ration of the SNP.
Culture of cardiomyocytes and NMD blocking
experiments
HL-1 cardiomyocytes [11] were cultured in Claycomb Medium
(SAFC Laboratories, Lenexa, KS) supplemented with Fetal Bovine
Serum at 10%, 2 mM L-Glutamine, 100 mg/ml Penicillin/
Streptomycin, and 100 mM fungizone. Cells were cultured at
37uC with 5% CO2. Although the HL-1 cardiomyocytes were
derived from a heart isolated from a mixed B6-DBA mouse [11]
direct sequencing of genomic DNA from the cell line showed that
it is homozygous for DBA alleles at the Tnni3k locus. HL-1 cells
were treated with 5.7610
22 mM cycloheximide or 3.3610
22 mM
emetine. Each treatment was performed in triplicate and RNA
was isolated from cells 24 hours post treatment. RT-PCR was
performed on RNA isolated from cells treated with NMD blocking
drugs and untreated controls. Ratios of properly spliced and
aberrantly spliced products were measured using the fluorescent
RT-PCR splicing assay as described above. Total transcript levels
were determined using the Tnni3k TaqMan assay described above.
Creation and testing of a TNNI3K transgenic mouse
A full-length 2.5 kb human TNNI3K cDNA was amplified from
normal human heart RNA following RT-PCR and cloned into a
vector downstream of the murine a-myosin heavy chain (aMHC)
promoter. An artificial minx intron was inserted upstream of the
TNNI3K start codon. The construct was linearized and an 8 kb
fragment containing the aMHC promoter, cDNA and SV40
polyadenylation sequence was purified and used for microinjec-
tion. B6SJLF1/J blastocysts were injected with the linearized
transgene and subsequently implanted into surrogate mice. The
resulting founder animals were genotyped for presence of the
TNNI3K transgene using a 59 primer in the aMHC promoter and
a3 9 primer in the TNNI3K transgene. Three transgenic lines were
chosen for backcrossing to the DBA strain. Western blot analysis of
heart lysates with a polyclonal antibody (Bethyl Laboratories,
Montgomery, TX) raised against a human C-terminal TNNI3K
peptide (FHSCRNSSSFEDSS) confirmed similar levels of expres-
sion of the TNNI3K transgene in each line (Figure S1). This was
repeated for several generations of backcrossing to DBA. Southern
blot analysis of DNA from founder animals and subsequent
generations (N2–N3) indicated that two founder lines carried 10–
20 copies of the transgene while the third line appeared to have
.100 copies. qRT-PCR with SYBRgreen (Invitrogen) was
performed on heart cDNA from several transgenic mice to
determine the relative expression difference between endogenous
mouse Tnni3k and transgenic human TNNI3K expression.
M-mode echocardiography
Transthoracic two-dimensional M-mode echocardiography was
performed between 12 and 18 weeks of age in conscious mice
using either a Vevo 770 echocardiograph (Visual Sonics, Toronto,
Canada) or an HDI 5000 echocardiograph with a 15-MHz
frequency probe (Phillips Electronics, Bothell, WA). Measurements
of cardiac function include heart rate, posterior and septal wall
thickness, left-ventricular end diastolic diameter (LVEDD) and
left-ventricular end systolic diameter (LVESD). Fractional short-
Tnni3k, a Genetic Modifier of Cardiomyopathy
PLoS Genetics | www.plosgenetics.org 9 September 2009 | Volume 5 | Issue 9 | e1000647ening (FS) was calculated with the formula: FS=(LVEDD2
LVESD)/LVEDD, as previously described [4].
Histology
Hearts were fixed in 10% neutral buffered formalin, dehydrated
in 75%, 90% and 100% ethanol, and embedded in paraffin;
sections 5 mm in thickness were cut and then stained with
Masson’s trichrome stain.
Transverse aortic constriction
Mice were anesthetized with a mixture of ketamine (100 mg/kg)
and xylazine (2.5 mg/kg), and transverse aortic constriction (TAC)
was performed as previously described [13]. TAC was performed
on 14 TNNI3K transgene-positive animals and 14 transgene-
negative (wild-type) littermates at 10 weeks of age. One of the
transgene-negative controls and three transgene-positive animals
died following surgery, which is a normal complication of this
procedure. The remaining 24 mice were then analyzed by
echocardiography (as described above), at 4 and 8 weeks following
the surgery.
Supporting Information
Figure S1 Calsequestrin and TNNI3K protein expression in
transgenic lines. (A) Calsequestrin protein expression detected in
Csq
tg and Csq
tg; TNNI3K
tg mice heart lysates using anti-CSQ
polycolonal antibody. A representative result is shown. (B) Stable
expression of human TNNI3K protein in two independent
transgenic lines. TNNI3K expression was detected in mice heart
lysates from both TNNI3K
tg lines using anti-TNNI3K polycolonal
antibody. A representative result is shown from N7 backcross
animals for both transgenic lines.
Found at: doi:10.1371/journal.pgen.1000647.s001 (0.49 MB TIF)
Table S1 Coding and representative non-coding polymorphic
SNPs from the mouse Tnni3k genomic region show two distinct
haplotype groups. The two SNP haplotypes correlate with Tnni3k
transcript levels. Group 1 (DBA, C3H, and BALB/c) show low
levels of Tnni3k while group 2 (B6, AKR, and 129Sv) show high
levels of Tnni3k.
Found at: doi:10.1371/journal.pgen.1000647.s002 (0.11 MB
DOC)
Table S2 M-mode echocardiograms of 14-day-old mice from a
cross between TNNI3K
tg and Csq
tg transgenic animals. Measure-
ments of cardiac function included left-ventricular end diastolic
diameter (LVEDD), left-ventricular end systolic diameter
(LVESD), posterior (PW) and septal (IVSW) wall thickness,
ejection time (ET), and heart rate (HR). Heart weight (HW) and
body weight (BW) were measured and the ratio of heart weight to
body weight was determined. Data is shown as mean6sd.
Found at: doi:10.1371/journal.pgen.1000647.s003 (0.07 MB
DOC)
Table S3 M-mode echocardiograms of Csq
tg transgenic mice on
the congenic background (DBA.AKR-Hrtfm2) at 4 and 8 weeks
ages, compared to their littermates with DBA Hrtfm2 alleles.
Measurements of cardiac function included left-ventricular end
diastolic diameter (LVEDD), left-ventricular end systolic diameter
(LVESD), posterior (PW) and septal (IVSW) wall thickness,
ejection time (ET), and heart rate (HR). Data is shown as
mean6sd.
Found at: doi:10.1371/journal.pgen.1000647.s004 (0.07 MB
DOC)
Table S4 M-mode echocardiograms for a surgically induced
model of cardiomyopathy. Echocardiography was performed prior
to transverse aortic constriction (TAC) and at 4- and 8-weeks post
TAC surgery on TNNI3K
tg mice and wild type littermates.
Measurements of cardiac function included left-ventricular end
diastolic diameter (LVEDD), left-ventricular end systolic diameter
(LVESD), posterior (PW) and septal (IVSW) wall thickness,
ejection time (ET), and heart rate (HR). Data is shown as
mean6sd.
Found at: doi:10.1371/journal.pgen.1000647.s005 (0.09 MB
DOC)
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